[{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"INDIA","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Levonorgestrel","moa":"||Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lupin Ltd \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Northumbria University","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Ferrous Bisglycinate","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Northumbria University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northumbria University \/ Bayer AG","highestDevelopmentStatusID":"1","companyTruncated":"Northumbria University \/ Bayer AG"},{"orgOrder":0,"company":"Northumbria University","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Ferrous Bisglycinate","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Northumbria University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northumbria University \/ Bayer AG","highestDevelopmentStatusID":"1","companyTruncated":"Northumbria University \/ Bayer AG"}]

Find Clinical Drug Pipeline Developments & Deals for Ferrous Bisglycinate

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          FNCE
                          Not Confirmed
                          FNCE
                          Not Confirmed

                          Details : Minzoya (levonorgestrel and ethinyl estradiol and ferrous bisglycinate Tablets) received approval from the US FDA, it is indicated for use by females of reproductive potential to prevent pregnancy.

                          Product Name : Minzoya

                          Product Type : Hormone

                          Upfront Cash : Inapplicable

                          January 13, 2025

                          Lead Product(s) : Levonorgestrel,Ethinyl Estradiol,Ferrous Bisglycinate

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Northumbria University

                          Country arrow
                          FNCE
                          Not Confirmed

                          Northumbria University

                          Country arrow
                          FNCE
                          Not Confirmed

                          Details : Iron Bis-Glycinate Chelate is a drug candidate, which is currently being evaluated in clinical studies for the treatment of Cerebral Blood Flow.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          July 20, 2020

                          Lead Product(s) : Ferrous Bisglycinate

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Undisclosed

                          Sponsor : Bayer AG

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Northumbria University

                          Country arrow
                          FNCE
                          Not Confirmed

                          Northumbria University

                          Country arrow
                          FNCE
                          Not Confirmed

                          Details : Iron Bis-Glycinate Chelate is a drug candidate, which is currently being evaluated in clinical studies for the treatment of Cognitive Dysfunction.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          July 13, 2020

                          Lead Product(s) : Ferrous Bisglycinate

                          Therapeutic Area : Neurology

                          Highest Development Status : Undisclosed

                          Sponsor : Bayer AG

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank